Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

This article was originally published here

The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the

The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply